A novel oral insulin-like growth factor-1 receptor pathway modulator and its implications for patients with non-small cell lung carcinoma: A phase I clinical trial

References

• Corvaia N, Beck A, Caussanel V, Goetsch L. Insulin-like growth factor receptor type I as a target for cancer therapy. Front Biosci (Schol Ed) 2013;5:439–50.
   PubMedGoogle Scholar
• Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008;8:915–28.
   PubMed Web of Science ®Google Scholar
• Karp DD, Paz-Ares LG, Novello S, Haluska P, Garland L, Cardenal F, et al. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol 2009;27:2516–22.
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Novello S. The role of the insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumors. Cancer Treat Rev 2012;38:292–302.
   PubMed Web of Science ®Google Scholar
• Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: An update. Nat Rev Cancer 2012;12: 159–69.
   PubMed Web of Science ®Google Scholar
• Girnita A, Girnita L, del Prete F, Bartolazzi A, Larsson O, Axelson M. Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res 2004;64:236–42.
   PubMed Web of Science ®Google Scholar
• Vasilcanu R, Vasilcanu D, Rosengren L, Natalishvili N, Sehat B, Yin S, et al. Picropodophyllin induces downregulation of the insulin-like growth factor 1 receptor: Potential mechanistic involvement of Mdm2 and beta-arrestin1. Oncogene 2008;27:1629–38.
   PubMed Web of Science ®Google Scholar
• Liu BY, Soloviev I, Huang X, Chang P, Ernst JA, Polakis P, et al. mammary tumor regression elicited by wnt signaling inhibitor requires IGFBP5. Cancer Res 2012;72:1568–78.
   PubMed Web of Science ®Google Scholar
• Duan Z, Choy E, Harmon D, Yang C, Ryu K, Schwab J, et al. Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines. Mol Cancer Ther 2009;8:2122–30.
   PubMed Web of Science ®Google Scholar
• Osuka S, Sampetrean O, Shimizu T, Saga I, Onishi N, Sugihara E, et al. IGF1 receptor signaling regulates adaptive radioprotection in glioma stem cells. Stem Cells 2013;31: 627–40.
   PubMed Web of Science ®Google Scholar
• Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010;18:683–95.
   PubMed Web of Science ®Google Scholar
• Fulzele K, DiGirolamo DJ, Liu Z, Xu J, Messina JL, Clemens TL. Disruption of the insulin-like growth factor type 1 receptor in osteoblasts enhances insulin signaling and action. J Biol Chem 2007;282:25649–58.
   PubMed Web of Science ®Google Scholar
• Lin FA, Larsson A, Strömberg T. Multiple antitumor effects of picropodophyllin in colon carcinoma cell lines: Clinical implications. Int J Oncol 2012;40:1251–8.
   PubMed Web of Science ®Google Scholar
• Wu X, Sooman L, Wickström M, Fryknäs M, Dyrager C, Lennartsson J, et al. Alternative cytotoxic effects of the postulated IGF-IR inhibitor picropodophyllin in vitro. Mol Cancer Ther 2013;12:1526–36.
   PubMed Web of Science ®Google Scholar
• Green CJ, Day M. Insulin-like growth factor 1 acts as an autocrine factor to improve early embryogenesis in vitro. Int J Dev Biol 2013;57:837–44.
   PubMed Web of Science ®Google Scholar
• Waraky A, Akopyan K, Parrow V, Strömberg T, Axelson M, Abrahmsén L, et al. Picropodophyllin causes mitotic arrest and catastrophe by depolymerizing microtubules via insulin-like growth factor-1 receptor-independent mechanism. Oncotarget 2014;5:8379–92.
   PubMed Web of Science ®Google Scholar
• Ekman S, Frödin J-E, Harmenberg J, Bergman A, Hedlund Å, Dahg P, et al. Clinical phase I study with an insulin-like growth factor-1 receptor inhibitor: Experiences in patients with squamous non-small cell lung carcinoma. Acta Oncol 2011;50:441–7.
   PubMed Web of Science ®Google Scholar
• Gascoigne KE, Taylor SS. How do anti-mitotic drugs kill cancer cells? J Cell Sci 2009;122:2579–85.
   PubMed Web of Science ®Google Scholar
• Le Tourneau C, Lee JJ, Siu LL. Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst 2009; 101:708–20.
   PubMed Web of Science ®Google Scholar
• Gualberto A, Alsina M, Lacy M, Poutney S, Birgin A, Littman B, et al. Inhibition of the insulin like growth factor 1 receptor by a specific monoclonal antibody in multiple myeloma. J Clin Oncol 2005;23:203s. abstr 3048.
   Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228–47.
   PubMed Web of Science ®Google Scholar
• Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009;50 (Suppl 1):122S–50S.
   PubMed Web of Science ®Google Scholar
• Rönquist-Nii Y, Eksborg S, Axelson M, Harmenberg J, Beck O. Determination of picropodophyllin and its isomer podophyllotoxin in human serum samples with electrospray ionization of hexylamine adducts by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2011;879:326–34.
   PubMed Web of Science ®Google Scholar
• Rowland M. Clinical pharmacokinetics: Concepts and applications, 3rd ed. Philadelphia: Wolters Kluwer Health/Lippincott William & Wilkins; 2011.
   Google Scholar
• Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O’Rourke M, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095–103.
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123–32.
   PubMed Web of Science ®Google Scholar
• Gualberto A, Karp DD. Development of the monoclonal antibody figitumumab, targeting the insulin-like growth factor-1 receptor, for the treatment of patients with non-small-cell lung cancer. Clin Lung Cancer 2009;10:273–80.
   PubMed Web of Science ®Google Scholar
• Gualberto A, Pollak M. Clinical development of inhibitors of the insulin-like growth factor receptor in oncology. Curr Drug Targets 2009;10:923–36.
   PubMed Web of Science ®Google Scholar
• Vasilcanu R, Vasilcanu D, Rosengren L, Natalishvili N, Sehat B, Yin S, et al. Picropodophyllin induces downregulation of the insulin-like growth factor 1 receptor: Potential mechanistic involvement of Mdm2 and [beta]-arrestin1. Oncogene 2008;27:1629–38.
   PubMed Web of Science ®Google Scholar
• Cohen BD, Baker DA, Soderstrom C, Tkalcevic G, Rossi AM, Miller PE, et al. Combination therapy enhances the inhibition of tumor growth with the fully human anti–type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 2005;11:2063–73.
   PubMed Web of Science ®Google Scholar
• Lacy MQ, Alsina M, Fonseca R, Paccagnella ML, Melvin CL, Yin D, et al. Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. J Clin Oncol 2008;26:3196–203.
   PubMed Web of Science ®Google Scholar
• Gualberto A, Pollak M. Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene 2009;28: 3009–21.
   PubMed Web of Science ®Google Scholar